Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colombel, J-F
Right arrow Articles by Cohard, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colombel, J-F
Right arrow Articles by Cohard, M
Gut 2001;49:42-46 ( July )

Article

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease J-F Colombela, P Rutgeertsb, H Malchowc, M Jacynad, O H Nielsene, J Rask-Madsenf, S Van Deventerg, A Fergusonh, P Desreumauxa, A Forbesd, K Geboesi, L Melanij, M Cohardj

a Gastroenterology Unit, Hopital Claude Huriez, Lille, France, b Department of Medicine, University of Leuven, Leuven, Belgium, c Klinikum Leverkusen, Leverkusen, Germany, d Department of Gastroenterology, Harrow, UK, e Department of Gastroenterology, Glostrup, Denmark, f Department of Gastroenterology, Herlev, Denmark, g Academic Medical Centre, Amsterdam, the Netherlands, h Department of Gastroenterology, Edinburgh, UK, i Department of Pathology, University of Leuven, Leuven, Belgium, j Schering-Plough Research Institute, Kenilworth, NJ, USA

Correspondence to: J F Colombel, Department of Gastroenterology, Hopital Huriez, CHU Lille, France. jfcolombel{at}chru-lille.fr

Accepted for publication 31 October 2000

BACKGROUND AND AIMS---New lesions of Crohn's disease occur early after ileal or ileocolonic resection and ileocolonic anastomosis. We performed a double blind controlled trial to evaluate the safety and tolerance of recombinant human interleukin 10 (IL-10; Tenovil) in subjects operated on for Crohn's disease. We also assessed the effect of Tenovil in preventing endoscopic recurrence 12 weeks after surgery.
METHODS---Patients with Crohn's disease who underwent curative ileal or ileocolonic resection and primary anastomosis were randomised within two weeks after surgery to receive subcutaneous Tenovil 4 µg/kg once daily (QD) (n=22) or 8 µg/kg twice weekly (TIW) (n=21), or placebo (QD or TIW) (n=22). An ileocolonoscopy was performed after 12 weeks of treatment.
RESULTS---Compliance was excellent. The most frequently observed adverse events were mild and moderate in severity and equally distributed across treatment groups. Thirty seven patients in the pooled Tenovil group and 21 patients in the pooled placebo group were evaluable by endoscopy. At 12 weeks, 11 of 21 patients (52%) in the placebo group had recurrent lesions compared with 17 of 37 patients (46%) in the Tenovil group (ns). The incidence of severe endoscopic recurrence was similar in both groups (9%).
CONCLUSION---Tenovil treatment for 12 consecutive weeks in patients with Crohn's disease after intestinal resection was safe and well tolerated. No evidence of prevention of endoscopic recurrence of Crohn's disease by Tenovil was observed.


Keywords: Crohn's disease; interleukin 10; endoscopic recurrence

© 2001 by Gut


This article has been cited by other articles:


Home page
 GutHome page
R Caprilli, M A Gassull, J C Escher, G Moser, P Munkholm, A Forbes, D W Hommes, H Lochs, E Angelucci, A Cocco, et al.
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations
Gut, March 1, 2006; 55(suppl_1): i36 - i58.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Ina, K. Kusugami, Y. Kawano, T. Nishiwaki, Z. Wen, A. Musso, G. A. West, M. Ohta, H. Goto, and C. Fiocchi
Intestinal Fibroblast-Derived IL-10 Increases Survival of Mucosal T Cells by Inhibiting Growth Factor Deprivation- and Fas-Mediated Apoptosis
J. Immunol., August 1, 2005; 175(3): 2000 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W J Sandborn and W A Faubion
Biologics in inflammatory bowel disease: how much progress have we made?
Gut, September 1, 2004; 53(9): 1366 - 1373.
[Full Text] [PDF]

Home page
 GutHome page
A Stallmach, T Marth, B Weiss, B M Wittig, A Hombach, C Schmidt, M Neurath, M Zeitz, S Zeuzem, and H Abken
An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo
Gut, March 1, 2004; 53(3): 339 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
K. Asadullah, W. Sterry, and H. D. Volk
Interleukin-10 Therapy--Review of a New Approach
Pharmacol. Rev., June 1, 2003; 55(2): 241 - 269.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen
Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential
Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D S Rampton
Crohn's disease recurrence can be prevented after ileal resection
Gut, August 1, 2002; 51(2): 153 - 154.
[Full Text] [PDF]

Home page
 GutHome page
H Herfarth and J Scholmerich
IL-10 therapy in Crohn's disease: at the crossroads
Gut, February 1, 2002; 50(2): 146 - 147.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2001 BMJ Publishing Group Ltd & British Society of Gastroenterology